May 8, 2025, 21:23

Rising Tide/LUNGevity Award for Improving the Early Detection of Lung Cancer through biomarkers and imaging

The Rising Tide Foundation for Clinical Cancer Research and the LUNGevity Foundation have announced a joint $1,000,000 grant opportunity to support clinical trials and validation studies aimed at significantly improving the early detection of lung cancer through the use of novel biomarkers, imaging technologies, or monitoring algorithms.

Who is eligible?

Applicants must:

Hold a doctoral degree and a faculty appointment (or equivalent) at an academic or research institution
Be an independent, self-directed investigator with institutional support
Have completed a postdoctoral training fellowship
Not currently hold another concurrent award from RTFCCR or LUNGevity
Collaborations and international teams are highly encouraged

Funding at a glance:

Up to $1,000,000 total (jointly funded by RTFCCR and LUNGevity)
Project duration: Up to 3 years
No indirect or overhead costs covered
Max 25% of budget for investigator salary/fringe benefits
Drug costs and investigator travel are not funded
Projects must include a fundraising plan for any additional operational costs

Research focus:

This RFA supports clinical research and validation studies (not early-stage biomarker discovery) that aim to:

Improve stratification criteria for defining high-risk lung cancer populations
Validate new early detection tests that could complement or replace LDCT screening
Develop non-invasive risk stratification tools for indeterminate pulmonary nodules (IPNs)

Projects must involve patient partners from the study’s conception to post-project dissemination, using a structured Patient Partner Involvement Plan.

Key deadlines:

Full Proposals Due: May 12, 2025
Award Notification: End of August 2025

Where to apply:

Submit all materials through the SmartSimple grant portal

Contact:

Dr. Upal Basu Roy (LUNGevity): [email protected]
Dr. Zoraide Granchi (RTFCCR): [email protected]

biomarkers cancer screening clinical trials early detection Imaging indeterminate pulmonary nodules Lung cancer LUNGevity Foundation non-invasive diagnostics OncoDaily Oncology patient-centered research proposalCENTRAL RTFCCR translational research

Carlos Rodriguez-Galindo: Childhood cancer has long been overlooked in global strategies - It is time to change that

EMBER-3 Trial Updates from ESMO Breast 2025: Imlunestrant Plus Abemaciclib Improves PFS in CDK4/6i-Pretreated ER+/HER2- Breast Cancer

FDA Grants Accelerated Approval for Telisotuzumab Vedotin (EMRELIS™) in c-MET–Overexpressing Advanced Non-Small Cell Lung Cancer

Oncologist Near Me – Wafik S. El-Deiry: A Global Leader in Translational Oncology and Cancer Research

In Memory of Bob Marley: His Battle with Melanoma and the Importance of Early Detection